Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03104569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 1, 2025 to Dec 1, 2028
    • Start date: Apr 1, 2025 to Apr 1, 2026
    v11
  2. Start date: Apr 1, 2024 to Apr 1, 2025v10
  3. Start date: Dec 1, 2023 to Apr 1, 2024v9
  4. Primary and study completion dates: Apr 1, 2025 to Dec 1, 2025
    • Start date: Jul 1, 2023 to Dec 1, 2023
    v8
  5. Primary and study completion dates: Apr 1, 2023 to Apr 1, 2025
    • Start date: Jul 1, 2017 to Jul 1, 2023
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised at 3 of 3 sites
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary and study completion dates: Apr 1, 2021 to Apr 1, 2023v6
  2. Primary and study completion dates: Apr 1, 2020 to Apr 1, 2021v5
  3. Primary and study completion dates: Apr 1, 2019 to Apr 1, 2020v4
  4. Primary and study completion dates: Apr 1, 2018 to Apr 1, 2019v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2017 to Jul 1, 2017
    • Site details revised at 3 of 3 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.
Trial Details
NCT Number NCT03104569
Lead Sponsor Hepatopancreatobiliary Surgery Institute of Gansu Province
Conditions
(from sponsor)		 Cholangitis
Related terms Cholangitis, Klatskin Tumor
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov